Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
O75390
UPID:
CISY_HUMAN
Alternative names:
Citrate (Si)-synthase
Alternative UPACC:
O75390; Q71UT9; Q7KZH0; Q96FZ8; Q9BWN8
Background:
Citrate synthase, mitochondrial, also known as Citrate (Si)-synthase, plays a pivotal role in the citric acid cycle. This enzyme catalyzes the synthesis of citrate from acetyl-CoA and oxaloacetate, marking the first step of the cycle critical for energy production in cells.
Therapeutic significance:
Understanding the role of Citrate synthase, mitochondrial could open doors to potential therapeutic strategies. Its central function in cellular metabolism positions it as a key target for research aimed at addressing metabolic disorders.